Loading...
Loading...
NKTR| Name | Value |
|---|---|
| Revenues | 23.5M |
| Cost of Revenue | 9.7M |
| Gross Profit | 13.7M |
| Operating Expense | 50.2M |
| Operating I/L | -36.5M |
| Other Income/Expense | -15.8M |
| Interest Income | 3.9M |
| Pretax | -52.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -52.4M |
Nektar Therapeutics is a biopharmaceutical company that focuses on discovering and developing medicines to address unmet medical needs. The company's product portfolio includes Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in various clinical trials for the treatment of cancer, as well as NKTR-358, a cytokine Treg stimulant, and NKTR-255, an IL-15 receptor agonist, in clinical trials for autoimmune diseases and cancer. Nektar Therapeutics generates revenue through the development and commercialization of these innovative drug candidates, as well as through collaboration agreements with leading pharmaceutical companies.
